Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions.
暂无分享,去创建一个
W. Symmans | W. Symmans | G. Inghirami | D. Knowles | D M Knowles | G Inghirami | J. Liu | W F Symmans | J Liu | Jiguan Liu
[1] J. Izbicki,et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.
[2] C. Cornelisse,et al. Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. , 1991, Cytometry.
[3] A. Campbell,et al. Aneuploid subpopulations in tumour-invaded lymph nodes from breast cancer patients. , 1992, European journal of cancer.
[4] G. Fleuren,et al. High levels of DNA index heterogeneity in advanced breast carcinomas. Evidence for DNA ploidy differences between lymphatic and hematogenous metastases , 1993, Cancer.
[5] J. Bacus,et al. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. , 1990, Archives of pathology & laboratory medicine.
[6] Y. Monden,et al. Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer , 1991, Cancer.
[7] H. Frierson. Ploidy Analysis and S‐Phase Fraction Determination by Flow Cytometry of Invasive Adenocarcinomas of the Breast , 1991, The American journal of surgical pathology.
[8] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[9] D. Visscher,et al. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. , 1990, Pathology annual.
[10] R. Camplejohn,et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. , 1990, British Journal of Cancer.
[11] I. Ellis,et al. An observation of DNA ploidy, histological grade, and immunoreactivity for tumour‐related antigens in primary and metastatic breast carcinoma , 1989, The Journal of pathology.
[12] P. Gimotty,et al. A retrospective analysis of breast cancer based on outcome differences. , 1991, Human pathology.
[13] P. Galand,et al. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues , 1989, Cell and tissue kinetics.
[14] R. Kerbel,et al. Cytogenetic heterogeneity of genetically marked and metastatically competent "dominant" tumor cell clones. , 1991, Cancer Genetics and Cytogenetics.
[15] A. Cornaglia,et al. Tissue fixation for immunohistochemical detection of proliferating cell nuclear antigen with PC10 monoclonal antibody. , 1994, Biotechnic & histochemistry : official publication of the Biological Stain Commission.
[16] P. Silcocks,et al. Delay in fixation does not affect the immunoreactivity of proliferating cell nuclear antigen (PCNA) , 1992, The Journal of pathology.
[17] R. Gelber,et al. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] R. Kerbel,et al. Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. , 1988, Cancer research.
[19] J. Fuhr,et al. Flow cytometric determination of breast tumor heterogeneity , 1991, Cancer.
[20] G. Mazzini,et al. Cell cycle‐related proteins: a flow cytofluorometric study in human tumors , 1988, Biology of the cell.
[21] F. Miller,et al. Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. , 1988, Cancer research.
[22] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[23] T. Singleton,et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.
[24] R. Kerbel,et al. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread , 1991, International Journal of Cancer.
[25] H. Wolf,et al. Detection of proliferating cell nuclear antigen in diagnostic histopathology. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[26] R. Kerbel. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. , 1990, Advances in cancer research.
[27] G. Fleuren,et al. Evidence for limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas. , 1993, Cancer research.
[28] P. V. van Diest,et al. Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material. , 1991, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[29] D. Lane,et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms , 1990, The Journal of pathology.
[30] J. H. Dierendonck,et al. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. , 1991, The American journal of pathology.
[31] L. Case,et al. The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients , 1990, Cancer.
[32] L. Ottestad,et al. The c-erbB-2 protein in primary and metastatic breast carcinomas. , 1991, Ultrastructural pathology.
[33] I. Fidler,et al. Changes in clonal composition during in vivo growth of mixed subpopulations derived from the murine K-1735 melanoma. , 1990, Anticancer research.
[34] B. Ljung,et al. Heterogeneity for allelic loss in human breast cancer. , 1992, Journal of the National Cancer Institute.
[35] P. V. van Diest,et al. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[36] M G Daidone,et al. Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]‐thymidine labelling index , 1990, Cell and tissue kinetics.
[37] J. Meyer,et al. Regional heterogeneity in breast carcinoma: Thymidine labelling index, steroid hormone receptors, dna ploidy , 1991, International journal of cancer.
[38] P. Frost,et al. Genotypic and phenotypic evidence of clonal interactions in murine tumor cells. , 1989, Journal of the National Cancer Institute.
[39] H. Joensuu,et al. The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up. , 1989, British Journal of Cancer.
[40] G. Heppner. Tumor cell societies. , 1989, Journal of the National Cancer Institute.
[41] Rochelle L. Garcia,et al. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. , 1989, The American journal of pathology.
[42] M. J. van de Vijver,et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.
[43] G. Auer,et al. Comparison of DNA distributions in primary human breast cancers and their metastases. , 1980, European journal of cancer.
[44] D. Schaid,et al. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.